Impetus Digital

DECEMBER 23, 2024

Pharma-exclusive Webinar: The 2025 Pharma Toolkit for Virtual Medical Education About the webinar Step into the future of medical education with our exclusive webinar series from February 25-26, designed specifically for Pharma leaders.

Education 110

Education Medical Pharma Training 110

MedCity News

MARCH 12, 2025

Roche will share in developing and commercializing petrelintide, a clinical-stage Zealand Pharma drug that activates the amylin receptor to spark weight loss. This agreement represents the highest total financial consideration in the obesity field to date.

Pharma 230

Pharma Biopharma 230

MedCity News

OCTOBER 9, 2024

If you thought that Big Pharma and the PBMs were the only bad guys in the saga of unreasonably high prescription drug prices in the United States, you would be wrong. The post Video: Besides, Pharma and PBMs, Who Drives Up Drug Costs? Hear who else is to blame from the CEO of Blue Shield of California.

Pharma 317

Pharma Prescription 317

MedCity News

JANUARY 23, 2025

Astellas Pharma still looks to grow in cancer with a pipeline that includes internally developed programs that could stand out in oncology. But the drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguci said.

Pharma 273

Pharma Medical Biopharma 273

MedCity News

OCTOBER 21, 2024

The post Astellas Pharma Lands a First-in-Class Drug Approval in Rare Gastrointestinal Cancer appeared first on MedCity News. The FDA approved Astellas’s Vyloy as a treatment for advanced cases of gastric or gastroesophageal junction (GEJ) adenocarcinoma positive for a protein called claudin 18.2.

Pharma 326

Pharma FDA Biopharma 326

MedCity News

JANUARY 31, 2025

The post Vertex Pharmas Opioid Alternative Wins FDA Approval, First in a New Class of Pain Meds appeared first on MedCity News. Vertex Pharmaceuticals Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain.

FDA 270

FDA Medicine Pharma Pharmaceutical 270

Fierce Pharma

NOVEMBER 1, 2024

said in an interview with Fierce Pharma. Now, less than a year later, the FDA is reconsidering those serious safety warnings with plans to potentially change them, CBER Director Peter Marks, M.D.,

FDA 284

FDA Safety Pharma Patients 284

MedCity News

OCTOBER 14, 2024

Longboard Pharma Acquisition appeared first on MedCity News. Last month, the biotech began a Phase 3 clinical trial testing the drug in Dravet syndrome. The post Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B

Pharma 311

Pharma Pharmaceutical Biopharma 311

MedCity News

NOVEMBER 4, 2024

This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity.

Pharma 300

Pharma FDA Leads Biopharma 300

MedCity News

SEPTEMBER 16, 2024

The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

Competition 313

Competition Pharma FDA Biopharma 313

MedCity News

OCTOBER 20, 2024

The post How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come appeared first on MedCity News. Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures.

Pharma 329

Pharma Leads Pharmaceutical Biopharma 329

MedCity News

OCTOBER 15, 2024

PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies. The post The Future of Hospitals and Pharma Companies Will Depend on Strength of Healthcare Analytics Insights appeared first on MedCity News.

Healthcare 291

Healthcare Healthcare Pharma Pharmaceutical 291

PharmaVoice

JANUARY 3, 2025

Pharma companies stepped up to support The Carter Center and provide access to life-saving treatments.

Pharma 279

Pharma 279

MedCity News

SEPTEMBER 24, 2024

The post Pain Meds, Cell Therapies & More: Vertex Pharma CEO Talks About What’s Next After Cystic Fibrosis appeared first on MedCity News. Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas.

Pharma 301

Pharma Pharmaceutical Medical Biopharma 301

Fierce Pharma

OCTOBER 23, 2024

The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and (..)

FDA 249

FDA Manufacturing Pharma 249

PharmaVoice

FEBRUARY 12, 2025

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

Pharma 263

Pharma Patients 263

MedCity News

SEPTEMBER 9, 2024

The post Terns Pharma Oral GLP-1 Drug Leads to Greater Than 5% Weight Loss in Small Study appeared first on MedCity News. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.

Leads 300

Leads Pharma Pharmaceutical Medical 300

MedCity News

DECEMBER 16, 2024

Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications. Novo Nordisks new Denmark site will produce drugs for rare diseases, such as hemophilias.

Manufacturing 259

Manufacturing Pharma Medical Biopharma 259

Evolve Your Success

FEBRUARY 5, 2025

Heres How Join the Medical Sales Podcast Community today: evolveyoursuccess.com This Podcast offers a pathway to continuing education via this CMEfy link: [link] The post Why I Went From Abbot Pharma Sales to 1099 With Bruce Brown first appeared on Evolve Your Success.

Sales 130

Sales Medical sales Pharma Medical 130

MedCity News

JANUARY 24, 2025

Ascentage Pharmas U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to develop and commercialize one of those drugs in most of the world. The post Ascentage Has First U.S.

Pharma 231

Pharma Leads Biopharma 231

Fierce Pharma

DECEMBER 2, 2024

Shortly after a similarly sized venture from Pfizer, French pharma juggernaut Sanofi has unveiled a major manufacturing outlay in China, marking its biggest investment in the country to date. Sanofi is laying out roughly 1 billion euros ($1.04

Manufacturing 232

Manufacturing Pharma 232

MedCity News

FEBRUARY 26, 2025

From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out The post Radiopharmaceutical Manufacturing: A High-Stakes (..)

Manufacturing 184

Manufacturing Pharma Management Biopharma 184

Fierce Pharma

OCTOBER 23, 2024

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court.

Pharma 215

Pharma 215

Fierce Pharma

OCTOBER 11, 2024

With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a deal is indeed brewing. Sanofi has entered negotiations with private equity outfit Clayton, Dubilier & Rice to potentially sell a 50% controlling stake in its consumer health business, Opella.

Pharma 195

Pharma 195

Fierce Pharma

NOVEMBER 26, 2024

German CDMO Adragos Pharma has been on a growth tear this year, drafting plans to boost capacity in Japan, upgrading a facility in France, taking over another from Fresenius Kabi in Norway and more | German CDMO Adragos Pharma has been on a growth tear this year.

Specialization 175

Specialization Networking Pharma Manufacturing 175

Fierce Pharma

OCTOBER 23, 2024

Now, a new complaint has surfaced—not from lawmakers or consumer groups but a major pharma CEO. While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks.

Pharma 203

Pharma 203

PharmaVoice

NOVEMBER 8, 2024

Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.

Pharma 280

Pharma Healthcare Healthcare 280

PharmaVoice

MARCH 17, 2025

billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product. The new $5.3

Pharma 130

Pharma 130

Fierce Pharma

SEPTEMBER 25, 2024

billion acquisition the New York pharma made two years ago. Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to a $5.4 Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide, a major blow to its $5.4

Marketing 321

Marketing Pharma 321

Fierce Pharma

OCTOBER 1, 2024

Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state, according to separate Worker Adjustment and Retraining Notification (WARN)

Pharma 318

Pharma 318

MedCity News

SEPTEMBER 27, 2024

The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety.

FDA 307

FDA Safety Pharma Biopharma 307

PharmaVoice

OCTOBER 28, 2024

Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.

Pharma 307

Pharma 307

Fierce Pharma

NOVEMBER 20, 2024

The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics. Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. |

Medicine 309

Medicine FDA Pharma 309

Fierce Pharma

OCTOBER 7, 2024

Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic, also known as semaglutide, India’s Natco Pharma said. With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S.

Pharma 309

Pharma Pharmaceutical 309

PharmaVoice

MARCH 10, 2025

Experts say cost and other barriers present challenges to returning to U.S.

Manufacturing 239

Manufacturing Pharma 239

PharmaVoice

JANUARY 10, 2025

Coming changes that could impact pharma from drug development to launch.

Pharma 247

Pharma 247

PharmaVoice

MARCH 13, 2025

has long been an opponent of pharma influence in government. HHS head Robert F. Kennedy Jr. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.

Government 217

Government Pharma 217